Stocks Health care ARQT
NASDAQ · Health careArcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. brought in $508.7M of revenue over the twelve months to September 30, 2026, up 60.0% from a year earlier. Net income was $29.9M, a net margin of 5.9%. In fiscal 2025 capital spending exceeded operating cash flow by $6.3M. At September 30, 2026 it held $33.4M in cash against $109.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Arcutis Biotherapeutics, Inc.
- Net worth
- Arcutis Biotherapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $244M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $376.1M (+91.3% year on year), with a net loss of $16.1M. Over the 12 months to September 30, 2026: revenue $508.7M, net income $29.9M.
- Cash flow
- In fiscal 2025 operations used $5.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arcutis Biotherapeutics, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Arcutis Biotherapeutics, Inc. does
Arcutis Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARQT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $376.1M | -$16.1M | -$0.13 | -$6.3M |
| 2024 | $196.5M | -$140M | -$1.16 | -$112.3M |
| 2023 | $59.6M | -$262.1M | -$3.78 | -$247.5M |
| 2022 | $3.7M | -$311.5M | -$5.66 | -$258M |
| 2021 | $0 | -$206.4M | -$4.18 | -$175.6M |
| 2020 | $0 | -$135.7M | -$3.80 | -$113.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ARQT ranks in Health care
Latest SEC filings
What Arcutis Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 45% to $143.9M versus the same quarter last year; diluted EPS $0.06 versus $0.06.
- November 4, 2026
- October 28, 2026
- October 5, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 59% to $129.9M versus the same quarter last year; diluted EPS $0.11 versus -$0.13.
- August 5, 2026
- July 16, 2026
- June 9, 2026
Insider trades
What the people running Arcutis Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.3M worth of shares in the last 90 days and bought none on the open market. Most of the selling (64%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Matsuda MasaruEVP, Chief Legal Officer | Exercised options | 40,000 | $145.6K |
| November 4, 2026 | Matsuda MasaruEVP, Chief Legal Officer | Soldpre-planned (10b5-1) | 40,000 | $1.4M |
| November 2, 2026 | Watanabe ToddSee Remarks, Director | Sold | 4,377 | $139.5K |
| November 2, 2026 | Burnett PatrickEVP, Chief Medical Officer | Sold | 943 | $30K |
| November 2, 2026 | Matsuda MasaruEVP, Chief Legal Officer | Soldpre-planned (10b5-1) | 1,219 | $38.8K |
| October 23, 2026 | Scott Robert ADirector | Received as pay | 2,819 | - |
| October 15, 2026 | Welgus Howard G.Director | Exercised options | 822 | $5.4K |
| October 15, 2026 | Welgus Howard G.Director | Exercised options | 1,018 | $7.6K |
Who owns ARQT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Patrick J. Heron13D, may seek influence with 19 related filers | 7.5% | August 20, 2025 |
| Rubric Capital Management LP13G, passive with 1 related filers | 6.75% | February 13, 2026 |
| Polar Capital Holdings Plc13G, passive with 1 related filers | 5.28% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 272 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 12,437,000 | +110,000 |
| BlackRock, Inc. | 10,545,466 | +1,345,055 |
| Frazier Life Sciences Management, L.P. | 9,874,511 | 0 |
| Rubric Capital Management LP | 8,271,577 | 0 |
| Polar Capital Holdings Plc | 6,606,945 | +940,005 |
| State Street Corp | 5,822,840 | -473,357 |
| Vanguard Capital Management LLC | 4,988,756 | +117,220 |
| Morgan Stanley | 4,451,014 | +232,083 |
| Jennison Associates LLC | 4,219,058 | -761,712 |
| D. E. Shaw & Co., Inc. | 3,949,609 | +1,453,387 |
| UBS Group AG | 3,333,015 | +3,791 |
| Bank of America Corp | 2,987,431 | +766,142 |
| Geode Capital Management, LLC | 2,982,446 | -62,860 |
| Vanguard Portfolio Management LLC | 2,429,005 | +474,320 |
| Orbimed Advisors LLC | 2,042,000 | new |
| Franklin Resources Inc | 1,930,982 | -366,961 |
| American Century Companies Inc | 1,925,031 | +461,803 |
| Goldman Sachs Group Inc | 1,668,367 | +65,354 |
| Jupiter Topco LLC | 1,410,435 | new |
| Oberweis Asset Management Inc/ | 1,372,941 | +7,000 |
Insiders
15 insiders reported holding 1,421,069 shares in total, about $38.6M at the last price.
| Holder | Shares |
|---|---|
| Watanabe ToddSee Remarks, Director | 712,826 |
| Edwards Larry ToddSee Remarks | 175,178 |
| Burnett PatrickEVP, Chief Medical Officer | 116,649 |
| Matsuda MasaruEVP, Chief Legal Officer | 111,289 |
| Vairavan LathaSVP Chief Financial Officer | 85,978 |
| Welgus Howard G.Director | 35,207 |
| Heron Patrick JDirector | 32,213 |
| Gilbert Halley EDirector | 27,901 |
| Leonard Keith RDirector | 27,901 |
| Krishnamohan NehaDirector | 27,901 |
Questions about ARQT
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ARQT. Its shares trade on NASDAQ under the ticker ARQT.
What is Arcutis Biotherapeutics, Inc.'s net worth?
Arcutis Biotherapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $244M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arcutis Biotherapeutics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $29.9M on revenue of $508.7M, a net margin of 5.9%.
How much revenue does Arcutis Biotherapeutics, Inc. make?
Over the twelve months to September 30, 2026 Arcutis Biotherapeutics, Inc. reported revenue of $508.7M. That is 60.0% more than a year earlier.
When did Arcutis Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Arcutis Biotherapeutics, Inc.'s next earnings report?
Arcutis Biotherapeutics, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARQT with
Follow ARQT
Get an email when Arcutis Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arcutis Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.